Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11033589 | Journal of Cancer Policy | 2018 | 26 Pages |
Abstract
Our results indicate that providers responded to reimbursement changes after the MMA by increasing use of newly approved agents, but the magnitude of the response was small and limited to individuals diagnosed with Stage IV disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Helen M. PhD, Susanne PhD, Laura L. MD, Amy J. PhD,